{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:49:15Z","timestamp":1776253755433,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.adro.2026.101997","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:16:22Z","timestamp":1770970582000},"page":"101997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Magnetic Resonance Imaging-Directed Stereotactic Body Radiation Therapy Microboost in Concert With Pelvic Nodal Irradiation for Prostate Cancer in the Higher-Risk Spectrum: Toxicity"],"prefix":"10.1016","volume":"11","author":[{"given":"Mina","family":"Musthafa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brianna","family":"Vizcaino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vianca F.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Kowalcyzk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Hankins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Lepor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-7757","authenticated-orcid":false,"given":"Jonathan W.","family":"Lischalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.adro.2026.101997_bib0001","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prostate cancer. Version 2.2025. Accessed August 19, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459"},{"key":"10.1016\/j.adro.2026.101997_bib0002","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","article-title":"Dose escalation for prostate adenocarcinoma: A long-term update on the outcomes of a phase 3, single institution randomized clinical trial","volume":"104","author":"Pasalic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.101997_bib0003","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(14)70040-3","article-title":"Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial","volume":"15","author":"Dearnaley","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2026.101997_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.adro.2026.101997_bib0005","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.101997_bib0006","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.adro.2026.101997_bib0007","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): Outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.101997_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.101997_bib0009","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2026.101997_bib0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2026.101997_bib0011","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: A systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.101997_bib0012","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2024.01.021","article-title":"Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results from a phase 2 clinical trial","volume":"85","author":"Nikitas","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.adro.2026.101997_bib0013","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: A combined analysis of 23 prospective clinical trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.adro.2026.101997_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2020.10.039","article-title":"High dose per fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): an overview","volume":"110","author":"Grimm","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2026.101997_bib16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.euo.2025.05.027","article-title":"Pooled analysis of the SOLAR and SATURN clinical trials comparing progression of synchronous versus metachronous prostate-specific membrane antigen-defined oligometastatic prostate cancer following systemic and tumor-directed therapy","volume":"8","author":"Juarez Casillas","year":"2025","journal-title":"Eur Urol Oncol"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109426000047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109426000047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:54:33Z","timestamp":1776250473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109426000047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2452109426000047"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2026.101997","relation":{},"ISSN":["2452-1094"],"issn-type":[{"value":"2452-1094","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Magnetic Resonance Imaging-Directed Stereotactic Body Radiation Therapy Microboost in Concert With Pelvic Nodal Irradiation for Prostate Cancer in the Higher-Risk Spectrum: Toxicity","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2026.101997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101997"}}